Story here. AZ spending major dollars for some pipeline enhancement therapy.
At least the two companies are within a semi-reasonable geographical proximity, making it easier for some folks to join the acquiring company (though many will undoubtedly be laid off).
The WSJ Health Blog speculates on who may be next. Will there be ANY mid-sized pharma or biotech companies left after next year??